JGC
EWTX icon

J. Goldman & Co’s Edgewise Therapeutics EWTX Stock Holding History

J. Goldman & Co’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,200
Closed -$1.26M – 518
2024
Q3 		$1.26M Buy
+47,200
New +$939K 0.04% 267

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

J. Goldman & Co's EWTX Position: Q1 2026 in Review

J. Goldman & Co opened a new position in Edgewise Therapeutics (EWTX) in Q1 2026: 61,421 shares worth $1.93M. The stake represents 0.06% of the portfolio and ranks #322 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in EWTX as recently as Q4 2024.

J. Goldman & Co first reported a position in EWTX in Q3 2024 and has held it in 3 quarters since. The position peaked at $2.86M in Q4 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • J. Goldman & Co held 61,421 shares of Edgewise Therapeutics worth $1.93M as of Q1 2026.
  • Edgewise Therapeutics was a new J. Goldman & Co position in Q1 2026.
  • Edgewise Therapeutics made up 0.06% of J. Goldman & Co's portfolio in Q1 2026, its #322 holding.
  • J. Goldman & Co first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • J. Goldman & Co's Edgewise Therapeutics position peaked at $2.86M in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.